- Previous Close
2.2000 - Open
2.5000 - Bid --
- Ask --
- Day's Range
2.2305 - 2.6100 - 52 Week Range
0.5080 - 6.1700 - Volume
2,457,028 - Avg. Volume
3,142,693 - Market Cap (intraday)
26.229M - Beta (5Y Monthly) --
- PE Ratio (TTM)
22.80 - EPS (TTM)
0.1000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.
www.impactbiomedinc.comRecent News: IBO
View MorePerformance Overview: IBO
Trailing total returns as of 3/27/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IBO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IBO
View MoreValuation Measures
Market Cap
26.23M
Enterprise Value
31.63M
Trailing P/E
22.51
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.84
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
10.07
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-4.99%
Return on Equity (ttm)
3.45%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
1.17M
Diluted EPS (ttm)
0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
2.67M
Total Debt/Equity (mrq)
23.31%
Levered Free Cash Flow (ttm)
-1.33M